Ramos, C., Montaño, E., Reyes-López, A., Lemus, F., Pacheco, M., Hernandez, G. and Lemus, A. 2019. Economic evaluation of lenalidomide (Revlimid®) for the treatment of mielodysplastic syndrome with 5q deletion at low/intermediate-1 risk: Evaluación Económica de Lenalidomida (Revlimid®) Para el Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q de Riesgo Bajo/Intermedio-1. Global and Regional Health Technology Assessment. 4, 1 (Nov. 2019), 133–140. DOI:https://doi.org/10.33393/grhta.2017.387.